{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-033556","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.914938+00:00","generated_at":"2026-05-25T10:08:51.253253+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sight Sciences reports Q4 revenue $19.1M (+2% YoY); guides FY2025 revenue down 6%-12%","bullets":["Q4 total revenue $19.1M (+2% YoY); Surgical Glaucoma $18.8M (+9%), Dry Eye $0.3M (down from $1.6M).","FY2024 net loss $51.5M ($1.03/shr) vs $55.5M ($1.14/shr) prior; cash used $17.8M (62% improvement YoY).","FY2025 revenue guidance $70M-$75M (6%-12% decline) citing new Medicare LCDs restricting MIGS coverage with cataract.","Adj. operating expenses FY2025 guided $105M-$107M (+4-6%); next-gen OMNI expected H1 2025.","Gross margin Q4 87% vs 85% prior; cash and equivalents $120.4M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-033556","json":"https://secwatch.observer/filing/0000950170-25-033556.json","markdown":"https://secwatch.observer/filing/0000950170-25-033556.md","text":"https://secwatch.observer/filing/0000950170-25-033556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017025033556/0000950170-25-033556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017025033556/sght-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T10:08:51.253253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}